Skip to main content

ASCPT 2023 Annual Meeting Main banner

Tweets by ASCPT 2023 Annual Meeting

Browse by Poster Title

Browse by Poster Title

Type here to filter the list

All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
#

C
PI-076
CANNABIDIOL EXPOSURES IN BREASTFED INFANTS COMPARED TO CHILDREN AS PREDICTED BY PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING.

Favorite
PT-017
CARDIOVASCULAR SAFETY OF CARFILZOMIB IN KOREA: RETROSPECTIVE COHORT STUDY USING A NATIONWIDE ADMINISTRATIVE CLAIM DATABASE.

Favorite
PI-085
CEFEPIME PHARMACOKINETICS IN CRITICALLY ILL CHILDREN UNDERGOING CONTINUOUS RENAL REPLACEMENT THERAPY (CRRT).

Favorite
EP-007
CENTRAL ADMINISTRATION OF COCAINE- AND AMPHETAMINE-REGULATED TRANSCRIPT PEPTIDE REDUCES CISPLATIN-INDUCED EMESIS AND C-FOS EXPRESSION IN SUNCUS MURINUS.

Favorite
PWIII-003
CHARACTERISTICS OF PROVIDERS WHO RESPONDED TO PASSIVE CLINICAL DECISION SUPPORT ALERTS FOLLOWING PRE-EMPTIVE RETURN OF PHARMACOGENOMIC RESULTS.

Favorite
PI-023
CHARACTERISTICS OF PROVIDERS WHO RESPONDED TO PASSIVE CLINICAL DECISION SUPPORT ALERTS FOLLOWING PRE-EMPTIVE RETURN OF PHARMACOGENOMIC RESULTS.

Favorite
PI-043
CHARACTERIZATION OF GEMTUZUMAB OZOGAMICIN PHARMACOKINETICS IN ADULT PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA FOLLOWING FRACTIONATED DOSING REGIMEN.

Favorite
PI-083
CHARACTERIZATION OF THE US FOOD AND DRUG ADMINISTRATION POST-MARKETING COMMITMENTS AND REQUIREMENTS FOR PREGNANCY AND LACTATION.

Favorite
PI-097
CHARACTERIZING ANTIHYPERTENSIVE MEDICATION USAGE IN APPARENT TREATMENT-RESISTANT HYPERTENSION (aTRH) PATIENTS WITHIN THE STATE OF FLORIDA USING ELECTRONIC HEALTH RECORD (EHR)-BASED DATA.

Favorite
RWE-010
CHARACTERIZING ANTIHYPERTENSIVE MEDICATION USAGE IN APPARENT TREATMENT-RESISTANT HYPERTENSION (aTRH) PATIENTS WITHIN THE STATE OF FLORIDA USING ELECTRONIC HEALTH RECORD (EHR)-BASED DATA.

Favorite
PI-011
CHARACTERIZING THE RELATIONSHIP BETWEEN CELLULAR KINETICS AND RESPONSE TO SUPPORT DOSING RECOMMENDATIONS FOR CD19-TARGETED 19(T2)28Z1XX CELL THERAPY.

Favorite
PI-024
CHRONIC NON-STEROIDAL ANTI-INFLAMMATORY DRUG (NSAID) USE INCREASES GASTRIC TOXICITY: A PHARMACOGENOMIC ANALYSIS.

Favorite
PT-028
CLINICAL ASSESSMENT OF THE DRUG INTERACTION POTENTIAL OF THE PSYCHOTROPIC NATURAL PRODUCT KRATOM (MITRAGYNA SPECIOSA).

Favorite
PI-044
CLINICAL DRUG–DRUG INTERACTION STUDIES TO EVALUATE THE EFFECTS OF BEMPEDOIC ACID, A SMALL-MOLECULE INHIBITOR OF ATP CITRATE LYASE, ON THE PHARMACOKINETICS OF CONCOMITANT STATIN THERAPIES.

Favorite
PI-012
CLINICAL EFFICACY OF CAR-T AND CAR-NK FOR THE TREATMENT OF HEMATOLOGIC AND SOLID TUMOR MALIGNANCIES: A SYSTEMATIC REVIEW AND META-ANALYSIS.

Favorite
PI-045
COMPARATIVE PHARMACOKINETICS BETWEEN DA-2811, A DAPAGLIFLOZIN PRODRUG FORMULATION, AND CONVENTIONAL DAPAGLIFLOZIN TABLET.

Favorite
PI-046
COMPARISON OF A COLORIMETRIC ASSAY AND ULTRA-PERFORMANCE LIQUID CHROMATOGRAPHY TANDEM MASS SPECTROMETRY FOR QUANTIFYING PARACETAMOL PLASMA CONCENTRATIONS: DESIGN OF A GERIATRIC PHARMACOKINETICS STUDY.

Favorite
PI-086
COMPARISON OF DISEASE CHARACTERISTICS IN ADULTS AND CHILDREN WITH TYPE 2 DIABETES MELLITUS: IMPLICATION FOR ANTIDIABETIC DRUG DEVELOPMENT IN CHILDREN.

Favorite
PI-047
COMPARISON OF PATIENT-CENTRIC MICROSAMPLING VS. TRADITIONAL BLOOD SAMPLING FOR PHARMACOKINETIC ANALYSIS OF ABROCITINIB.

Favorite
PI-048
COMPARISON OF PHARMACOKINETICS AND PHARMACODYNAMICS OF HIP1802 AND NEXIUM®: A RANDOMIZED, OPEN-LABEL, MULTIPLE DOSE, CROSSOVER TRIAL.

Favorite
PI-013
COMPARISON OF PREDICTED OVERALL SURVIVAL TO OBSERVED CLINICAL DATA IN PATIENTS WITH BRAF V600-MUTANT METASTATIC MELANOMA TREATED WITH ENCORAFENIB ALONE OR ENCORAFENIB + BINIMETINIB.

Favorite
PI-049
COMPARISON OF THE ACID SUPPRESSION EFFECTS BETWEEN LOW-DOSE ESOMEPRAZOLE AND FAMOTIDINE IN HEALTHY SUBJECTS.

Favorite
PII-001
COMPARISON OF THE IMMUNOGENICITY RISK OF BIOTHERAPEUTICS ADMINISTERED VIA INTRAVENOUS VS. SUBCUTANEOUS ROUTE OF ADMINISTRATION.

Favorite
PI-050
COMPARISON OF THE SYSTEMIC EXPOSURE AND PREDICTED INHIBITION OF PHARMACODYNAMIC CYTOKINE RESPONSE BY SYSTEMIC AND LOCALLY ACTING JAK INHIBITORS.

Favorite
PT-011
COMPUTATIONAL SYSTEMS PHARMACOLOGY OF ANTIBODY-DRUG CONJUGATES.

Favorite
PII-053
CONCENTRATION-QT MODELING ANALYSIS OF GEMTUZUMAB OZOGAMICIN FOLLOWING FRACTIONATED DOSING REGIMEN IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA.

Favorite
PI-051
CONCENTRATION-QTC ANALYSIS TO ASSESS THE EFFECT OF THE GS-5718 ON CARDIAC REPOLARIZATION.

Favorite
RWE-002
CONCURRENT GABAPENTIN AND OPIOID USE AND RISK OF MORTALITY IN MEDICARE RECIPIENTS WITH NON-CANCER PAIN.

Favorite
PT-013
CONCURRENT GABAPENTIN AND OPIOID USE AND RISK OF MORTALITY IN MEDICARE RECIPIENTS WITH NON-CANCER PAIN.

Favorite
PII-121
CONTRIBUTION OF INFLAMMATION AND OBESITY TO VARIABILITY IN MIDAZOLAM PHARMACOKINETICS IN CHILDREN.

Favorite
PI-052
CYCLOPHOSPHAMIDE POPULATION PHARMACOKINETICS IN PEDIATRIC PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION.

Favorite